TICKERNERD
Menu
PTGXPTGXHealthcare · Biotechnology

PTGX Stock Forecast: Protagonist Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$149
+1.86% on the day

The 13 Wall Street analysts covering Protagonist Therapeutics, Inc. hold a median 12-month price target of $171 — +14.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 2 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$9.5B
Ticker Nerd rank
97 / 100
Median analyst target
$171
Analysts covering
13
Revenue$213.5M+3749.2% y/y
Operating income$158.8M
Net income$162.8M
Free cash flow$218.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
+12.5%
YTD
+70.4%
1Y
+156.1%
From 52W high
−6.2%
From 52W low
+164.8%
$56
$159
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Protagonist Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
94
Momentum
88
Growth
84
Quality
84
Revisions
80
Accruals
67
Issuance
54
Size
16

Volatility (99): The share price has been relatively steady.

Issuance (54): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26PTGXHigh $225Median $171Low $149

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $149Median $171High $225

The green dot is the last close — the median target sits +14.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
31 Aug 2026HC Wainwright & Co.MaintainsBuy$167 → $170
17 Aug 2026BMO CapitalMaintainsOutperform$112 → $178
10 Aug 2026Goldman SachsUpgradeBuy$110 → $186
10 Aug 2026Truist SecuritiesMaintainsBuy$145 → $170
10 Aug 2026WedbushMaintainsOutperform$118 → $173
6 Aug 2026BarclaysMaintainsOverweight—
6 Aug 2026BarclaysMaintainsOverweight$151 → $153
6 Aug 2026CitigroupMaintainsBuy—
6 Aug 2026CitigroupMaintainsBuy$130 → $175
14 July 2026BarclaysMaintainsOverweight—
14 July 2026BarclaysMaintainsOverweight$119 → $151
7 July 2026Truist SecuritiesMaintainsBuy$121 → $145
7 July 2026Truist SecuritiesMaintainsBuy—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026WedbushMaintainsOutperform—
15 Apr 2026Truist SecuritiesMaintainsBuy—
7 Apr 2026Clear StreetMaintainsBuy—
19 Mar 2026BarclaysMaintainsOverweight—
19 Mar 2026CitigroupMaintainsBuy—
19 Mar 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PTGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Protagonist Therapeutics, Inc. returned +156.1% against +21.4% for the S&P 500, dividends included.

PTGX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26PTGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PTGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+15.6%
Analysts raising
5
Analysts cutting
0
Fundamentals

Protagonist Therapeutics, Inc. (PTGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
141.8×

Cheaper than 5% of US stocks

Price / sales
33.5×

Cheaper than 7% of US stocks

Price / book
11.2×

Cheaper than 9% of US stocks

EV / EBITDA
145.4×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
3749.2%

Higher than 99% of US stocks

Earnings growth (YoY)
3749.2%

Higher than 99% of US stocks

Gross margin
—
Operating margin
74.4%

Higher than 99% of US stocks

Net margin
29.4%

Higher than 89% of US stocks

Returns & dividend
Return on equity
11.0%

Higher than 65% of US stocks

Return on assets
4.5%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Protagonist Therapeutics, Inc. (PTGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Protagonist Therapeutics, Inc. has a market value of $9.5B and an enterprise value of $8.7B.

  • Revenue in the twelve months to 30 June 2026: $282.0M. The latest quarter grew 3749.2% year on year.

  • Net income over the same four quarters: $82.9M, a 29.4% net margin.

  • Diluted earnings per share, trailing twelve months: $1.03.

  • Free cash flow in the twelve months to 30 June 2026: $130.6M.

  • Shares outstanding: 64.7M.

  • Trailing P/E: 141.8×; forward P/E: −733.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Protagonist Therapeutics, Inc. employs 141 people — $2.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

PTGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTGXProtagonist Therapeutics, Inc.$9.5B
97
TGTXTG Therapeutics, Inc.$9.0B
68
IONSIonis Pharmaceuticals, Inc.$9.8B
48
PRAXPraxis Precision Medicines, Inc.$9.8B
44
KYMRKymera Therapeutics, Inc.$9.9B
73
PCVXVaxcyte, Inc.$8.7B
53
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Protagonist Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTGX news & analysis

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

Accesswire · 2 Sept 2026neutral

Protagonist Therapeutics announced that Dinesh V. Patel, Ph.D. will participate in two investment bank conferences scheduled for September 2026. The announcement, made from the company's Newark, CA headquarters, confirms the company's planned presence at these upcoming investor events.

Why it matters — PTGX watchers would care because conference participation offers investors an opportunity to hear directly from company leadership about the business.

Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript

Seeking Alpha · 31 Aug 2026positive

Protagonist Therapeutics, Inc. held a discussion regarding the FDA approval of Mimrylo for erythrocytosis in polycythemia vera, as covered in a Seeking Alpha transcript of the event. The item centers on this regulatory approval discussion for the company's product.

Why it matters — A PTGX watcher would care because the FDA approval of Mimrylo for erythrocytosis in polycythemia vera represents a significant regulatory milestone for the company's pipeline and commercial prospects.

Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment

MarketBeat · 31 Aug 2026positive

The FDA has approved Protagonist Therapeutics' rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare blood cancer. This is a regulatory approval for one of the company's key pipeline products.

Why it matters — A PTGX watcher would care because this FDA approval brings a key investigational treatment to the market and represents a significant regulatory milestone for the company's portfolio.

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

The Motley Fool · 31 Aug 2026neutral

A Motley Fool article discusses Johnson & Johnson's portfolio, which primarily consists of stakes in 15 small biotech and medtech companies. J&J's largest investment is in the portfolio company with the largest market capitalization.

Why it matters — J&J's investments in small biotech companies are relevant to PTGX watchers because Protagonist Therapeutics operates in the biotech sector and could be among the type of companies J&J holds stakes in.

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

Accesswire · 29 Aug 2026positive

Protagonist Therapeutics announced that Takeda received U.S. FDA approval for MIMRYLO (rusfertide), a first-in-class hepcidin mimetic peptide for treating erythrocytosis in adults with polycythemia vera. The approval is supported by Phase 3 VERIFY results showing 76.9% of patients achieved response during weeks 20-32, and triggers milestone payments and royalties for Protagonist.

Why it matters — This FDA approval of MIMRYLO, Protagonist's lead hepcidin mimetic candidate, triggers $275 million in milestones and ongoing royalties, representing a major commercial milestone for the company.

FAQ

Frequently asked questions about PTGX stock

What is the PTGX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Protagonist Therapeutics, Inc. have a median 12-month price target of $171, with estimates ranging from $149 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTGX stock a buy right now?

Of the 13 analysts covering Protagonist Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protagonist Therapeutics, Inc. 97 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTGX?

As at 2 Sept 2026, Protagonist Therapeutics, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will PTGX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +14.9% from the last close, and Ticker Nerd's factor model ranks Protagonist Therapeutics, Inc. 97 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTGX stock forecast for 2030?

No analyst covering Protagonist Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $149 to $225 over the next 12 months.

How has PTGX stock performed over the past year?

Protagonist Therapeutics, Inc. returned +156.1% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapies for serious diseases.

What is the latest news on PTGX?

The most recent item we track (Accesswire, 2 Sept 2026): "Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026". Protagonist Therapeutics announced that Dinesh V. Patel, Ph.D. will participate in two investment bank conferences scheduled for September 2026. The announcement, made from the company's Newark, CA headquarters, confirms the company's planned presence at these upcoming investor events.

Company

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapies for serious diseases. Using a proprietary peptide technology platform, the company advances drug candidates designed to address unmet needs in inflammation and immunology, hematology, and metabolic disease. Its current programs center on differentiated medicines such as rusfertide and oral peptide candidates developed for immune-mediated and blood disorders, reflecting a strategy built around targeted mechanisms and convenient routes of administration. Protagonist Therapeutics works across research, clinical development, and collaboration-based programs to create therapies with potential use in conditions where existing treatment options are limited or inadequate. Headquartered in Newark, California, Protagonist Therapeutics plays a specialized role in the biopharmaceutical market by focusing on peptide innovation and translational medicine.

CEO Dr. Dinesh V. Patel Ph.D. · 141 employees · United States · https://www.protagonist-inc.com